SS-31 vs Glutathione (GSH)
Both SS-31 and Glutathione (GSH) are used for longevity. Here's how their evidence, dosing, and regulatory status actually compare.
SS-31
Evidence B+Elamipretide (SS-31)
A cell-permeable tetrapeptide that targets cardiolipin in the inner mitochondrial membrane. Investigated for primary mitochondrial myopathy, heart failure, and dry age-related macular degeneration.
View full SS-31 profile →Glutathione (GSH)
Evidence BReduced L-Glutathione
Technically a tripeptide (γ-glutamyl-cysteinyl-glycine) and the body's primary antioxidant. Often grouped with peptide therapy in IV/compounded form for liver support and oxidative stress.
View full Glutathione (GSH) profile →Side-by-Side
| Attribute | SS-31 | Glutathione (GSH) |
|---|---|---|
| Evidence Grade | B+ | B |
| FDA Status | Not FDA-approved — Phase 3 trials for primary mitochondrial myopathy | Not FDA-approved as therapeutic — sold as supplement; intravenous use compounded |
| Typical Dose | Trial range: 40 mg subcutaneous daily | 200–600 mg sublingual / 600–2400 mg IV (compounded) |
| Clinics Indexed | 29 | 312 |
| Categories | mitochondrial, longevity | antioxidant, longevity |
Key reported benefits — SS-31
- ✓Mitochondrial cardiolipin support
- ✓ATP production
- ✓Reduced oxidative damage
Key reported benefits — Glutathione (GSH)
- ✓Master antioxidant
- ✓Liver detoxification support
- ✓Oxidative stress reduction
Educational use only
This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.